Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOviricid lozenges in newly diagnosed COVID-19
NCT04601077Phase 2Terminated
- Sponsor
- Nitric Oxide Innovations, LLC
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Nitric Oxide Innovations, LLC. Primary endpoints: Low Blood Pressure at 30 days and Dizziness at 30 days. Started Nov 2020; status: terminated.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04601077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601077.